CLEAR CARE PLUS CLEANING AND DISINFECTING SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

HYDROGEN PEROXIDE

Prieinama:

ALCON CANADA INC

ATC kodas:

S01XA20

INN (Tarptautinis Pavadinimas):

ARTIFICIAL TEARS AND OTHER INDIFFERENT PREPARATIONS.

Dozė:

3%

Vaisto forma:

SOLUTION

Sudėtis:

HYDROGEN PEROXIDE 3%

Vartojimo būdas:

DISINFECTANT (Contact Lens)

Vienetai pakuotėje:

90/360/480ML

Recepto tipas:

OTC

Gydymo sritis:

CONTACT LENS SOLUTIONS

Produkto santrauka:

Active ingredient group (AIG) number: 0106899001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2020-12-10

Prekės savybės

_ _
_CLEAR CARE* PLUS Cleaning and Disinfecting Solution _
_Page 1 of 22_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CLEAR CARE* PLUS
CLEANING AND DISINFECTING SOLUTION
3% Hydrogen Peroxide
Professed Standard
Contact Lens Disinfectant
Alcon Canada Inc.
2665 Meadowpine Blvd.
Mississauga, ON, L5N 8C7
Date of Preparation:
December 11, 2015
Date of Revision:
Submission Control No: 177795
*a Trademark of Novartis
©2015 Novartis
_ _
_CLEAR CARE* PLUS Cleaning and Disinfecting Solution _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................7
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
............................................................